Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,265
archived clinical trials in
Rheumatoid Arthritis

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
559
mi
from 43215
Rochester, MN
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
559
mi
from 43215
Rochester, MN
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
660
mi
from 43215
Jackson, MS
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
660
mi
from 43215
Jackson, MS
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
627
mi
from 43215
St. Joseph, MO
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
627
mi
from 43215
St. Joseph, MO
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
1751
mi
from 43215
Henderson, NV
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
1751
mi
from 43215
Henderson, NV
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
609
mi
from 43215
Lebanon, NH
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
609
mi
from 43215
Lebanon, NH
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
468
mi
from 43215
Newark, NJ
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
468
mi
from 43215
Newark, NJ
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
481
mi
from 43215
New York, NY
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
302
mi
from 43215
Ashville, NC
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
302
mi
from 43215
Ashville, NC
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
127
mi
from 43215
Cleveland, OH
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
127
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
752
mi
from 43215
Tulsa, OK
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
752
mi
from 43215
Tulsa, OK
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
527
mi
from 43215
Charleston, SC
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
527
mi
from 43215
Charleston, SC
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
362
mi
from 43215
Chattanooga, TN
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
362
mi
from 43215
Chattanooga, TN
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
910
mi
from 43215
Dallas, TX
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
422
mi
from 43215
Norfolk, VA
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
422
mi
from 43215
Norfolk, VA
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
335
mi
from 43215
Milwaukee, WI
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
335
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Mobile Diagnostic Center Rheumatology
700
mi
from 43215
Mobile, AL
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Mobile Diagnostic Center Rheumatology
700
mi
from 43215
Mobile, AL
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Valerius Medical Group
1977
mi
from 43215
Long Beach, CA
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Valerius Medical Group
1977
mi
from 43215
Long Beach, CA
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Trial Concierge/Pacific Clinical Studies
1970
mi
from 43215
Los Alamitos, CA
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Trial Concierge/Pacific Clinical Studies
1970
mi
from 43215
Los Alamitos, CA
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Axis Clinical Trials
1977
mi
from 43215
Los Angeles, CA
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Axis Clinical Trials
1977
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Riverside Clinical Research
767
mi
from 43215
Edgewater, FL
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Riverside Clinical Research
767
mi
from 43215
Edgewater, FL
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Global Clinical Professionals
996
mi
from 43215
Miami, FL
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Global Clinical Professionals
996
mi
from 43215
Miami, FL
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
The Arthritis Center
821
mi
from 43215
Palm Harbor, FL
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
The Arthritis Center
821
mi
from 43215
Palm Harbor, FL
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Lakeview Medical Research
758
mi
from 43215
Summerfield, FL
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Lakeview Medical Research
758
mi
from 43215
Summerfield, FL
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Analan Clinical Research
628
mi
from 43215
Lenexa, KA
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Analan Clinical Research
628
mi
from 43215
Lenexa, KA
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Trial Concierge
267
mi
from 43215
Owensboro, KY
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Trial Concierge
267
mi
from 43215
Owensboro, KY
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Quality Clinical Research, Inc.
688
mi
from 43215
Omaha, NE
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Quality Clinical Research, Inc.
688
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Advanced Biomedical Research of America
1758
mi
from 43215
Las Vegas, NV
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Advanced Biomedical Research of America
1758
mi
from 43215
Las Vegas, NV
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Arthritis Center of Reno
1940
mi
from 43215
Reno, NV
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Arthritis Center of Reno
1940
mi
from 43215
Reno, NV
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Pmg Research Of Salisbury
328
mi
from 43215
Salisbury, NC
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Pmg Research Of Salisbury
328
mi
from 43215
Salisbury, NC
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Providence Health Partners
63
mi
from 43215
Dayton, OH
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Providence Health Partners
63
mi
from 43215
Dayton, OH
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Paramount Medical Research & Consulting, Llc
116
mi
from 43215
Middleburg Heights, OH
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Paramount Medical Research & Consulting, Llc
116
mi
from 43215
Middleburg Heights, OH
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
The Center for Excellence in Aging and Geriatric Health
389
mi
from 43215
Williamsburg, VA
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
The Center for Excellence in Aging and Geriatric Health
389
mi
from 43215
Williamsburg, VA
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Apex Clinical Research
1854
mi
from 43215
Kennewick, WA
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Apex Clinical Research
1854
mi
from 43215
Kennewick, WA
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
South Puget Sound Clinical Research Center
2033
mi
from 43215
Olympia, WA
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
South Puget Sound Clinical Research Center
2033
mi
from 43215
Olympia, WA
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
492
mi
from 43215
Birmingham, AL
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
1662
mi
from 43215
Phoenix, AZ
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
1662
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
2091
mi
from 43215
Santa Clara, CA
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
2091
mi
from 43215
Santa Clara, CA
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
522
mi
from 43215
Bridgeport, CT
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
522
mi
from 43215
Bridgeport, CT
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
395
mi
from 43215
Newark, DE
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
395
mi
from 43215
Newark, DE
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
749
mi
from 43215
Daytona Beach, FL
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
749
mi
from 43215
Daytona Beach, FL
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
430
mi
from 43215
Decatur, GA
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
430
mi
from 43215
Decatur, GA
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
1748
mi
from 43215
Coeur D Alene, ID
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
1748
mi
from 43215
Coeur D Alene, ID
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
288
mi
from 43215
Park Ridge, IL
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
288
mi
from 43215
Park Ridge, IL
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
166
mi
from 43215
Indianapolis, IN
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
188
mi
from 43215
Louisville, KY
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
188
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
797
mi
from 43215
Metairie, LA
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
797
mi
from 43215
Metairie, LA
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
344
mi
from 43215
Baltimore, MD
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
344
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
643
mi
from 43215
Boston, MA
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials